---
title: "Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer"
date: 2016-08-23
publishDate: 2020-07-25T00:35:04.158427Z
authors: 
    - Daniel L. Hertz
    - Kelley M. Kidwell
    - nseewald
    - Christina L. Gersch
    - Zeruesenay Desta
    - David A. Flockhart
    - Ana-Maria Storniolo
    - Vered Stearns
    - Todd C. Skaar
    - Daniel F. Hayes
    - N. Lynn Henry
    - James M. Rae
publication_types: ["article-journal"]

hugoblox:
    ids:
        doi: "10.1038/tpj.2016.60"

links:
    - name: PubMed
      url: http://pubmed.ncbi.nlm.nih.gov/27549341
      icon: academicons/pubmed

abstract: "Discovery of clinical and genetic predictors of exemestane pharmacokinetics was attempted in 246 postmenopausal patients with breast cancer enrolled on a prospective clinical study. A sample was collected 2â€‰h after exemestane dosing at a 1- or 3-month study visit to measure drug concentration. The primary hypothesis was that patients carrying the low-activity CYP3A4*22 (rs35599367) single-nucleotide polymorphism (SNP) would have greater exemestane concentration. Additional SNPs in genes relevant to exemestane metabolism (CYP1A1/2, CYP1B1, CYP3A4, CYP4A11, AKR1C3/4, AKR7A2) were screened in secondary analyses and adjusted for clinical covariates. CYP3A4*22 was associated with a 54% greater exemestane concentration (P<0.01). Concentration was greater in patients who reported White race, had elevated aminotransferases, renal insufficiency, lower body mass index and had not received chemotherapy (all P<0.05), and CYP3A4*22 maintained significance after adjustment for covariates (P<0.01). These genetic and clinical predictors of exemestane concentration may be useful for treatment individualization in patients with breast cancer."
featured: false
publication: "*The Pharmacogenomics Journal*"
tags: ["cancer", collaboration, masters]
projects: [cancer-biomarkers]
---
